

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:07:08 ON 29 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2003 HIGHEST RN 506405-59-0
DICTIONARY FILE UPDATES: 27 APR 2003 HIGHEST RN 506405-59-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can tot 141

L41 ANSWER 1 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN 415678-15-8 REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-[[4-(1H-imidazol-4-ylmethyl)phenyl]methyl]-4-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H21 N5 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

L41 ANSWER 2 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN 415678-14-7 REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, N-[(3,5-difluorophenyl)methyl]-6-ethoxy-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H15 F2 N3 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

L41 ANSWER 3 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN **304680-79-3** REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H19 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

L41 ANSWER 4 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN **220861-17-6** REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-[[3-[(methylamino)methyl]phenyl]methyl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)
MF C20 H22 N4 O3 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (304680-89-5)



● HCl

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 130:196645

L41 ANSWER 5 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-95-7 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-[[4-[(methylamino)methyl]phenyl]methyl]-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C20 H22 N4 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 6 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-93-5 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-(dimethylamino)-1,4-dihydro-4-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H16 N4 O2 S

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 7 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-92-4** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 1,4-dihydro-6-(4-morpholinyl)-4-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C18 H18 N4 O3 S

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225


REFERENCE 4: 130:196645

L41 ANSWER 8 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-90-2** REGISTRY

CN 1,5-Naphthyridine-3-carboxamide, 1,4-dihydro-6-(2-methoxyethoxy)-4-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C17 H17 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 130:196645

L41 ANSWER 9 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN 220860-81-1 REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-[(4-methylphenyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H19 N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972


REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 10 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN 220860-75-3 REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-[(4-

methoxyphenyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H19 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 11 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN 220860-74-2 REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-N-[(4-fluorophenyl)methyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H16 F N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 12 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN 220860-72-0 REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-N-[(2-fluorophenyl)methyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H16 F N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 13 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN 220860-70-8 REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-(3-thienylmethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H15 N3 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 14 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN 220860-68-4 REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-(1H-imidazol-4-ylmethyl)-4-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H15 N5 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 15 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN 220860-67-3 REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1,4-dihydro-6-methoxy-4-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H14 F N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 16 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-66-2** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, N-[(3-fluorophenyl)methyl]-1,4-dihydro-6-methoxy-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C17 H14 F N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)

4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 17 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-65-1** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, N-[(2-fluorophenyl)methyl]-1,4-dihydro-6-methoxy-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C17 H14 F N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)

4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 18 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-64-0** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 1,4-dihydro-6-methoxy-4-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C17 H15 N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)

4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 19 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-62-8** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-(5-hydroxypentyl)-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H21 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 20 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-60-6 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-(2-methylbutyl)-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H21 N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 21 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-59-3 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-N-(3-ethoxypropyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H21 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 22 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-58-2 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-[(3-methoxyphenyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C19 H19 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 23 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-56-0 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-(3-methylbutyl)-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H21 N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 24 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-52-6** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C17 H21 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 130:196645

L41 ANSWER 25 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-50-4** REGISTRY

CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-[(phenyl)methyl]- (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C18 H17 N3 O3

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 26 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-48-0** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-pentyl-
(9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H21 N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225


REFERENCE 4: 130:196645

L41 ANSWER 27 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-47-9** REGISTRY

CN 1,5-Naphthyridine-3-carboxamide, N-butyl-6-ethoxy-1,4-dihydro-4-oxo- (9CI)
(CA INDEX NAME)

FS 3D CONCORD
MF C15 H19 N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 28 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-45-7 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, N-butyl-6-chloro-1,4-dihydro-4-oxo- (9CI)
(CA INDEX NAME)

FS 3D CONCORD

MF C13 H14 Cl N3 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972


REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 29 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-44-6 REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-(phenylmethyl)-, monopotassium salt (9CI) (CA INDEX NAME)
MF C18 H17 N3 O3 . K
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (220860-50-4)




● K

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 133:335225

REFERENCE 2: 130:196645

L41 ANSWER 30 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN 220860-43-5 REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-(phenylmethyl)-, monosodium salt (9CI) (CA INDEX NAME)
MF C18 H17 N3 O3 . Na
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (220860-50-4)



● Na


2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 133:335225

REFERENCE 2: 130:196645

L41 ANSWER 31 OF 31 REGISTRY COPYRIGHT 2003 ACS
RN 220860-40-2 REGISTRY
CN 1,5-Naphthyridine-3-carboxamide, N-[2-(ethylthio)ethyl]-1,4-dihydro-6-methoxy-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C14 H17 N3 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 130:196645

=> d ide can tot 138

L38 ANSWER 1 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 415973-05-6 REGISTRY

CN Carbamic acid, ethylmethyl-, 3-[(1R)-1-(dimethylamino)ethyl]phenyl
ester (9CI) (CA INDEX NAME)

OTHER NAMES:

CN SDZ 212712


FS STEREOSEARCH

MF C14 H22 N2 O2

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:335150

L38 ANSWER 2 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 145508-78-7 REGISTRY

CN 6H-Pyrrolo[3,2-f]-1,2-benzisoxazol-6-one, 5,7-dihydro-3-[2-[1-

(phenylmethyl)-4-piperidinyloxyethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN CP 118954

CN **Icopezil**

FS 3D CONCORD


MF C23 H25 N3 O2

CI COM

SR CA

LC STN Files: ADISNEWS, BIOSIS, CA, CAPLUS, CASREACT, DDFU, DRUGNL,
DRUGPAT, DRUGU, DRUGUPDATES, IPA, SYNTHLINE, TOXCENTER, USAN, USPAT2,
USPATFULL

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19 REFERENCES IN FILE CA (1957 TO DATE)

19 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:149611

REFERENCE 2: 136:350581

REFERENCE 3: 136:319416

REFERENCE 4: 136:145265

REFERENCE 5: 135:339282

REFERENCE 6: 135:251415

REFERENCE 7: 133:344629

REFERENCE 8: 133:331554

REFERENCE 9: 132:329435

REFERENCE 10: 132:132346

L38 ANSWER 3 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 130791-77-4 REGISTRY

CN 5,9-Methanocycloocta[b]pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-, (5S,9S,11E)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5,9-Methanocycloocta[b]pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-, [5S-(5.alpha.,9.beta.,11E)]-

OTHER NAMES:

CN **(+)-Huperzine A**

CN (+)-Selagine


FS STEREOSEARCH

MF C15 H18 N2 O

SR CA

LC STN Files: ADISINSIGHT, AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAPLUS,
CASREACT, CHEMINFORMRX, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
15 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:259310
REFERENCE 2: 136:319270
REFERENCE 3: 136:161385
REFERENCE 4: 134:172932
REFERENCE 5: 133:105191
REFERENCE 6: 132:347771
REFERENCE 7: 132:166372
REFERENCE 8: 131:310755
REFERENCE 9: 129:28115
REFERENCE 10: 124:306513

L38 ANSWER 4 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 123441-03-2 REGISTRY

CN Carbamic acid, ethylmethyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl
ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Carbamic acid, ethylmethyl-, 3-[1-(dimethylamino)ethyl]phenyl ester,
(S)-

OTHER NAMES:

CN ENA 713 free base

CN Exelon

CN Rivastigmine

CN SDZ 212-713

FS STEREOSEARCH

MF C14 H22 N2 O2

CI COM


SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAPLUS, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, IPA, MEDLINE, MRCK*, PHAR, PHARMASEARCH, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

117 REFERENCES IN FILE CA (1957 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

118 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:248345

REFERENCE 2: 138:231759

REFERENCE 3: 138:200816

REFERENCE 4: 138:198432

REFERENCE 5: 138:180503

REFERENCE 6: 138:163577

REFERENCE 7: 138:147558

REFERENCE 8: 138:117580

REFERENCE 9: 138:65959

REFERENCE 10: 138:49850

L38 ANSWER 5 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 120014-06-4 REGISTRY

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (.+-.)-E 2020

CN Donepezil

FS 3D CONCORD

DR 142057-79-2

MF C24 H29 N O3

CI COM


SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MRCK*, MSDS-OHS, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2,

USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

217 REFERENCES IN FILE CA (1957 TO DATE)

6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

217 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:265145

REFERENCE 2: 138:248536

REFERENCE 3: 138:248535

REFERENCE 4: 138:248354

REFERENCE 5: 138:231759

REFERENCE 6: 138:231296

REFERENCE 7: 138:147599

REFERENCE 8: 138:130980

REFERENCE 9: 138:100818

REFERENCE 10: 138:83269

L38 ANSWER 6 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 120011-70-3 REGISTRY

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Aricept

CN BNAG

CN Donepezil hydrochloride

CN E 2020

CN E 2020 (pharmaceutical)

DR 142057-77-0


MF C24 H29 N O3 . Cl H

SR CA

LC STN Files: ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DIOGENES, DRUGPAT, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PHARMASEARCH, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

CRN (120014-06-4)



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

161 REFERENCES IN FILE CA (1957 TO DATE)
 8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 164 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:248536
 REFERENCE 2: 138:248535
 REFERENCE 3: 138:163577
 REFERENCE 4: 138:119337
 REFERENCE 5: 138:100847
 REFERENCE 6: 138:61310
 REFERENCE 7: 138:33350
 REFERENCE 8: 138:32709
 REFERENCE 9: 138:11346
 REFERENCE 10: 138:350

L38 ANSWER 7 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 105601-20-5 REGISTRY

CN Carbamic acid, ethylmethyl-, 3-[1-(dimethylamino)ethyl]phenyl ester
 (9CI) (CA INDEX NAME)

FS 3D CONCORD


DR 129101-52-6

MF C14 H22 N2 O2

CI COM

SR CA

LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, DRUGPAT, DRUGUPDATES,
 TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:55734
REFERENCE 2: 136:183572
REFERENCE 3: 134:305320
REFERENCE 4: 106:188457
REFERENCE 5: 106:4687

L38 ANSWER 8 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 102518-79-6 REGISTRY

CN 5,9-Methanocycloocta[b]pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-, (5R,9R,11E)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5,9-Methanocycloocta[b]pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-, [5R-(5.alpha.,9.beta.,11E)]-

CN Selagine (6CI, 8CI)

OTHER NAMES:

CN (-)-Huperzine A

CN (-)-Isoselagine

CN (-)-Selagine

CN Huperzine A

CN Isoselagine

CN Kimpukan A

FS STEREOSEARCH

DR 116-28-9, 1369-64-8, 92138-20-0

MF C15 H18 N2 O

CI COM


SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, NAPRALERT, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

218 REFERENCES IN FILE CA (1957 TO DATE)
23 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
220 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:248348
REFERENCE 2: 138:231596
REFERENCE 3: 138:210049
REFERENCE 4: 138:182260
REFERENCE 5: 138:163573
REFERENCE 6: 138:112410
REFERENCE 7: 138:8355
REFERENCE 8: 137:332983
REFERENCE 9: 137:316111
REFERENCE 10: 137:305894

L38 ANSWER 9 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 60384-53-4 REGISTRY

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aR,6S,8aR)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Galanthamine, (3.alpha.,4a.beta.,12a.beta.)-

OTHER NAMES:

CN **(+)-Galanthamine**

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, [4aR-(4a.alpha.,6.beta.,8aR*)]-

CN ent-Galanthamine


FS STEREOSEARCH

MF C17 H21 N O3

CI COM

LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15 REFERENCES IN FILE CA (1957 TO DATE)

15 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:237232
REFERENCE 2: 132:93500
REFERENCE 3: 131:149380
REFERENCE 4: 128:13368
REFERENCE 5: 127:135980
REFERENCE 6: 126:8355
REFERENCE 7: 125:196086
REFERENCE 8: 125:114933
REFERENCE 9: 123:112051
REFERENCE 10: 122:240093

L38 ANSWER 10 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 29347-10-2 REGISTRY

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aR,8aS)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 4.alpha.,12.alpha.-Physostigmine (8CI)

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aR-cis)-

OTHER NAMES:

CN **(+)-Physostigmine**

FS STEREOSEARCH


MF C15 H21 N3 O2

CI COM

LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, GMELIN*, IPA, NAPRALERT, TOXCENTER, USPATFULL

(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20 REFERENCES IN FILE CA (1957 TO DATE)

20 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:251277
REFERENCE 2: 131:19172
REFERENCE 3: 129:149126

REFERENCE 4: 127:162007
REFERENCE 5: 125:114929
REFERENCE 6: 124:33165
REFERENCE 7: 123:47400
REFERENCE 8: 122:255432
REFERENCE 9: 121:109333
REFERENCE 10: 120:134893

L38 ANSWER 11 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 357-70-0 REGISTRY

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl- (7CI)

CN Galanthamine (6CI, 8CI)

OTHER NAMES:

CN (-)-Galanthamine

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, [4aS-(4a.alpha.,6.beta.,8aR*)]-

CN Galantamin

CN **Galantamine**

CN Jilkon

CN Lycoremin

CN Lycoremine

CN [4aS-(4a.alpha.,6.beta.,8aR*)]-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol

FS STEREOSEARCH

DR 736-79-8, 1551-02-6


MF C17 H21 N O3

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HODOC*, IPA, MEDLINE, MRCK*, NAPRALERT, PHAR, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

577 REFERENCES IN FILE CA (1957 TO DATE)
21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
580 REFERENCES IN FILE CAPLUS (1957 TO DATE)
27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:231759
REFERENCE 2: 138:226433
REFERENCE 3: 138:217351
REFERENCE 4: 138:187161
REFERENCE 5: 138:165922
REFERENCE 6: 138:163577
REFERENCE 7: 138:137102
REFERENCE 8: 138:126979
REFERENCE 9: 138:89944
REFERENCE 10: 138:66100

L38 ANSWER 12 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 321-64-2 REGISTRY

CN 9-Acridinamine, 1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Acridine, 9-amino-1,2,3,4-tetrahydro- (7CI, 8CI)

CN Acridine, 9-aminotetrahydro- (6CI)

OTHER NAMES:

CN 1,2,3,4-Tetrahydro-9-acridinamine

CN 1,2,3,4-Tetrahydro-9-aminoacridine

CN 9-Amino-1,2,3,4-tetrahydroacridine

CN Tacrine

CN Tetrahydroaminacrine

CN Tetrahydroaminocrin

CN Tetrahydroaminocrine

CN THA


MF C13 H14 N2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES,
DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR,
PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

984 REFERENCES IN FILE CA (1957 TO DATE)
46 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
987 REFERENCES IN FILE CAPLUS (1957 TO DATE)
24 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:265139
REFERENCE 2: 138:250076
REFERENCE 3: 138:248481
REFERENCE 4: 138:231759
REFERENCE 5: 138:231651
REFERENCE 6: 138:226547
REFERENCE 7: 138:216760
REFERENCE 8: 138:205824
REFERENCE 9: 138:182260
REFERENCE 10: 138:182123

L38 ANSWER 13 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 57-47-6 REGISTRY

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-,
methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN **Physostigmine (8CI)**

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-,
methylcarbamate (ester), (3aS-cis)-

OTHER NAMES:

CN (-)-Eserine

CN (-)-Physostigmine

CN Cogmine

CN Eserine

CN Esromiotin

CN MCV 4484

CN NIH 10421

CN Physostol

FS STEREOSEARCH

DR 511-49-9; 50975-37-6

MF C15 H21 N3 O2

CI COM


LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ACQUIRE, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE,
GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*,
MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, RTECS*, SPECINFO,
SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3056 REFERENCES IN FILE CA (1957 TO DATE)
33 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3059 REFERENCES IN FILE CAPLUS (1957 TO DATE)
23 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:265053
REFERENCE 2: 138:200816
REFERENCE 3: 138:199058
REFERENCE 4: 138:198554
REFERENCE 5: 138:180962
REFERENCE 6: 138:180572
REFERENCE 7: 138:163213
REFERENCE 8: 138:148863
REFERENCE 9: 138:147175
REFERENCE 10: 138:142332

L38 ANSWER 14 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 52-68-6 REGISTRY

CN Phosphonic acid, (2,2,2-trichloro-1-hydroxyethyl)-, dimethyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN (.+-.)-Trichlorfon
CN 1-Hydroxy-2,2,2-trichloroethylphosphonate-O,O-dimethyl ester
CN Aerol 1 (pesticide)
CN Agroforotox
CN Anthon
CN BAY-a 9826
CN BAY-L 1359
CN Bayer L 13/59
CN Bayer L 1359
CN Chlorak
CN Chlorofos
CN Chloroftalm
CN Chlorophos

CN Chlorophthalm
 CN Chloroxyphos
 CN Comboto
 CN Danex
 CN DEP
 CN DEP (pesticide)
 CN Depthon
 CN DETF
 CN Dimethyl (2,2,2-trichloro-1-hydroxyethyl)phosphonate
 CN Dimethyl 1-hydroxy-2,2,2-trichloroethylphosphonate
 CN Dimetox
 CN Dioxaphos
 CN Dipterex
 CN Dipterex 50
 CN Dipterex 500
 CN Dipterex SL
 CN Dipterex WP. 80
 CN Diptevur
 CN Ditrifon
 CN Ditrifon 50
 CN Dylox
 CN Dyrex
 CN Dyvon
 CN ENT 19,763
 CN Flibol E
 CN Fliegenteller
 CN Forotox
 CN Foschlor
 CN Foschlor R
 CN Foschlor R 50
 CN Hypodermacid
 CN Loisol
 CN Masoten
 CN Mazoten
 CN Methyl chlorophos
 CN **Metrifonate**
 CN Metriphonate

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

FS 3D CONCORD

DR 56042-25-2, 66758-31-4, 50924-44-2, 37333-09-8

MF C4 H8 Cl3 O4 P


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
 CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*,
 DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IFICDB,
 IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR,
 PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER,
 ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5141 REFERENCES IN FILE CA (1957 TO DATE)
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5144 REFERENCES IN FILE CAPLUS (1957 TO DATE)
297 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:267208
REFERENCE 2: 138:267201
REFERENCE 3: 138:251130
REFERENCE 4: 138:233389
REFERENCE 5: 138:233382
REFERENCE 6: 138:231759
REFERENCE 7: 138:223306
REFERENCE 8: 138:200332
REFERENCE 9: 138:200331
REFERENCE 10: 138:200308

=> d ide can 19

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 9000-81-1 REGISTRY

CN Esterase, acetyl choline (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Acetyl .beta.-methylcholinesterase

CN Acetylcholine acetylhydrolase

CN Acetylcholine esterase

CN Acetylcholine hydrolase

CN Acetylcholinesterase

CN Acetylthiocholinesterase

CN E.C. 3.1.1.7

DR 9026-02-2

MF Unspecified

CI MAN

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
CA, CABA, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN,
CSCHEM, CSNB, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS,
NIOSHTIC, PROMT, TOXCENTER, ULIDAT, USPAT2, USPATFULL

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

16319 REFERENCES IN FILE CA (1957 TO DATE)
187 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
16335 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:268006
REFERENCE 2: 138:267525
REFERENCE 3: 138:267067
REFERENCE 4: 138:267066

REFERENCE 5: 138:265813
REFERENCE 6: 138:265139
REFERENCE 7: 138:265036
REFERENCE 8: 138:264963
REFERENCE 9: 138:255460
REFERENCE 10: 138:253331

=> d ide can l10

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 56-12-2 REGISTRY

CN Butanoic acid, 4-amino- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Butyric acid, 4-amino- (7CI, 8CI)

OTHER NAMES:

CN .gamma.-Aminobutanoic acid

CN .gamma.-Aminobutyric acid

CN .gamma.-Aminobutyric acid

CN .omega.-Aminobutyric acid

CN 3-Carboxypropylamine

CN 4-Aminobutanoic acid

CN 4-Aminobutyric acid

CN Aminalton

CN GABA

CN Gaballon

CN Gamarex

CN Gammalon

CN Gammalone

CN Gammar

CN Gammamol

CN Mielogen

CN Mielomade

CN Piperidic acid

CN Piperidinic acid

FS 3D CONCORD

DR 3131-86-0

MF C4 H9 N O2

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

$\text{H}_2\text{N}-(\text{CH}_2)_3-\text{CO}_2\text{H}$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

24700 REFERENCES IN FILE CA (1957 TO DATE)

427 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
24727 REFERENCES IN FILE CAPLUS (1957 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:276296
REFERENCE 2: 138:270633
REFERENCE 3: 138:270445
REFERENCE 4: 138:268682
REFERENCE 5: 138:268275
REFERENCE 6: 138:265970
REFERENCE 7: 138:265959
REFERENCE 8: 138:265958
REFERENCE 9: 138:265954
REFERENCE 10: 138:265942

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 16:09:24 ON 29 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Apr 2003 VOL 138 ISS 18
FILE LAST UPDATED: 28 Apr 2003 (20030428/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot 148

L48 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:695763 HCAPLUS
DN 137:210972
TI Use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders
IN **Villalobos, Anabella**
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English

IC ICM A61K031-00
ICS C07D471-04; A61P025-28
CC 1-11 (Pharmacology)
Section cross-reference(s): 2, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002069948	A1	20020912	WO 2002-IB515	20020220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002193360	A1	20021219	US 2002-83743	20020226
PRAI	US 2001-272566P	P	20010301		
OS	MARPAT 137:210972				
AB	<p>A pharmaceutical compn. and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a GABAA inverse agonist or a pharmaceutically acceptable salt thereof; and a nicotine receptor partial agonist, an estrogenic agent, selective estrogen receptor modulator or vitamin E or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The GABAA inverse agonist, and nicotine receptor partial agonist, estrogen, selective estrogen receptor modulator or vitamin E are present in amts. that render the compn. effective enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease, Huntington's disease, memory impairment assocd. with depression or anxiety, schizophrenia, Down's syndrome, stroke, traumatic brain injury (TBI), AIDS assocd. dementia and attention deficit disorder. The method of using these compns. is also disclosed.</p>				
ST	cognitive disorder treatment GABAA inverse agonist combination;				
IT	nicotine receptor partial agonist combination cognitive disorder treatment				
IT	GABA agonists (GABAA, inverse agonists; use of GABAA inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)				
IT	GABA receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (GABAA, .alpha.5 subtype; use of GABAA inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)				
IT	Drug delivery systems (carriers; use of GABAA inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)				
IT	Mental disorder (cognitive; use of GABAA inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)				
IT	Cognition (disorder; use of GABAA inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)				
IT	Estrogen receptors RL: BSU (Biological study, unclassified); BIOL (Biological study)				

(modulators; use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)

IT Nicotinic agonists
(partial; use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)

IT Cognition enhancers
Drug interactions
(use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)

IT Nicotinic receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders).

IT Estrogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)

IT 1406-18-4, Vitamin E 69718-72-5 207391-08-0 207391-10-4
207391-12-6 207391-15-9 207391-18-2 207391-21-7 207391-24-0
207391-27-3 207391-28-4 207391-29-5 207391-34-2 207391-36-4
207391-37-5 207391-38-6 207391-39-7 207391-40-0 207391-41-1
207391-42-2 207391-44-4 207391-63-7 207391-64-8 207391-65-9
207391-67-1 207391-74-0 220860-40-2 220860-45-7
220860-47-9 220860-48-0 220860-50-4
220860-52-6 220860-56-0 220860-58-2
220860-59-3 220860-60-6 220860-62-8
220860-64-0 220860-65-1 220860-66-2
220860-67-3 220860-68-4 220860-70-8
220860-72-0 220860-74-2 220860-75-3
220860-81-1 220860-90-2 220860-92-4
220860-93-5 220860-95-7 220861-17-6
248275-68-5 248275-79-8 248275-81-2 248275-95-8 248276-19-9
249296-44-4 287973-23-3 287973-26-6 287973-27-7 304680-79-3
328055-77-2 328055-78-3 328055-79-4 328055-80-7 328055-81-8
328055-84-1 328055-85-2 328055-86-3 328055-87-4 328055-88-5
328055-89-6 328055-90-9 328055-92-1 328055-94-3 328055-95-4
328055-96-5 328055-97-6 328055-99-8 328056-00-4 328056-01-5
328056-02-6 328056-03-7 328056-04-8 328056-05-9 328056-06-0
328056-07-1 328056-08-2 328056-09-3 328056-10-6 328056-11-7
328056-12-8 328056-13-9 328056-14-0 328056-15-1 328056-21-9
328056-22-0 328056-23-1 328056-24-2 328056-25-3 328056-26-4
328056-27-5 328056-28-6 328056-29-7 328056-30-0 328056-66-2
357424-19-2 367511-27-1 367511-30-6 367511-38-4 415678-14-7
415678-15-8 457634-09-2 457634-13-8 457634-14-9
457634-15-0 457634-16-1 457634-17-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

- (1) Desimone, R; WO 9910347 A 1999 HCAPLUS
- (2) Neurogen Corp; WO 0071528 A 2000 HCAPLUS

DN 136:319416
 TI Combination of **acetylcholinesterase** inhibitors and **GABAA**
 inverse agonists for the treatment of cognitive disorders
 IN Villalobos, Anabella; Cassella, James Vincent;
 Rajachandran, Lavanya
 PA Pfizer Products Inc., USA; Neurogen Corporation
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-00
 CC 1-11 (Pharmacology)
 Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032412	A2	20020425	WO 2001-IB1934	20011015
	WO 2002032412	A3	20030320		
	W:	AE, AG, AL, AM, AT , AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN , IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002151591	A1	20021017	US 2001-976347	20011012
	AU 2001094117	A5	20020429	AU 2001-94117	20011015
PRAI	US 2000-241145P	P	20001017		
	WO 2001-IB1934	W	20011015		
OS	MARPAT 136:319416				
GI					



AB This invention provides a compn. for treating a cognitive disorder, which comprises an **acetylcholinesterase**, and a **GABAA** inverse agonist selected from a compd. (I, where X = e.g., H, halo, Ph, naphthyl, pyridinyl; Y = e.g., C1-8 alkyl, carbocycle). Thus, **aricept** and a **GABAA** inverse agonist (e.g., N-benzyl-6-ethoxy-4-oxo-1,4-tetrahydro-1,5-naphthyridine-3-carboxamide), when coadministered, interact to attenuate scopolamine-induced deficits in the spatial water maze.

ST **acetylcholinesterase** inhibitor **GABAA** agonist cognitive enhancer; **aricept** tetrahydronaphthyridinecarboxamide cognitive enhancer


IT **GABA** agonists
 (GABAA; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)

IT Mental disorder
 (attention deficit disorder; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)

- IT Mental disorder
(cognitive; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Anti-Alzheimer's agents
Antiparkinsonian agents
Cognition enhancers
Down's syndrome
Drug delivery systems
Memory, biological
Psychotropics
(combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Mental disorder
(dementia, vascular; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Cognition
(disorder; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Drug delivery systems
(prodrugs; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Brain, disease
(stroke; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Drug interactions
(synergistic; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Brain, disease
(trauma; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT 52-68-6, Metrifonate 57-47-6,
Physostigmine 321-64-2, Tacrine
357-70-0, Galantamine 102518-79-6,
Huperzine A 120011-70-3, Aricept
123441-03-2, Rivastigmine 145508-78-7,
Icopezil 220860-40-2 220860-45-7
220860-47-9 220860-48-0 220860-50-4
220860-52-6 220860-56-0 220860-58-2
220860-59-3 220860-60-6 220860-62-8
220860-64-0 220860-65-1 220860-66-2
220860-67-3 220860-68-4 220860-70-8
220860-72-0 220860-74-2 220860-75-3
220860-81-1 220860-90-2 220860-92-4
220860-93-5 220860-95-7 220861-17-6
304680-79-3 415678-14-7 415678-15-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT 9000-81-1, **Acetylcholinesterase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- L48 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:785902 HCAPLUS
DN 133:335225
TI Substituted 4-oxo-naphthyridine-3-carboxamides: **GABA** brain
receptor ligands

IN Albaugh, Pamela A.; Desimone, Robert W.; Liu, Gang
 PA Neurogen Corp., USA
 SO U.S., 27 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A61K031-44
 ICS C07D471-02
 NCL 514300000
 CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6143760	A	20001107	US 1998-139456	19980825
	ZA 9807957	A	20000322	ZA 1998-7957	19980901
	US 6399604	B1	20020604	US 2000-634093	20000808
	US 2002156280	A1	20021024	US 2002-114743	20020402
PRAI	US 1997-56799P	P	19970825		
	US 1998-139456	A1	19980825		
	US 2000-634093	A1	20000808		
OS	MARPAT 133:335225				
GI					



AB The present invention encompasses substituted 4-oxo-naphthyridine-3-carboxamides I or the pharmaceutically acceptable nontoxic salts of I (X = H, halogen, (un)substituted alkyl, (un)substituted alkoxy or amino; and Y is (un)substituted alkyl, aryl, or heteroaryl). I are highly selective agonists, antagonists or inverse agonists for **GABA_A** brain receptors or prodrugs of agonists, antagonists or inverse agonists for **GABA_A** brain receptors. I are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.

ST oxonaphthyridinecarboxamide prepn **GABA** brain receptor ligand

IT **GABA** agonists

GABA antagonists

(**GABA_A**; prepn. of substituted 4-oxo-naphthyridine-3-carboxamides as **GABA** brain receptor ligands)

IT Sleep

(disorder; prepn. of substituted 4-oxo-naphthyridine-3-carboxamides in treatment of)

IT Amides, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(naphthyridine-3-carboxamides; prepn. of substituted 4-oxo-naphthyridine-3-carboxamides as **GABA** brain receptor ligands)

IT Anxiety

Down's syndrome

Seizures

(prepn. of substituted 4-oxo-naphthyridine-3-carboxamides in treatment

of)

IT 100961-91-9P
 RL: BYP (Byproduct); PREP (Preparation)
 (formation in prepn. of substituted 4-oxo-naphthyridine-3-carboxamides
 as agonists, antagonists or inverse agonists for **GABA_A** brain
 receptors)

IT 220860-38-8P 220860-41-3P 220860-42-4P **220860-43-5P**
220860-44-6P **220860-45-7P** 220860-46-8P
220860-47-9P **220860-48-0P** 220860-49-1P
220860-50-4P 220860-51-5P 220860-53-7P 220860-54-8P
 220860-55-9P **220860-56-0P** 220860-57-1P **220860-58-2P**
220860-59-3P **220860-60-6P** 220860-61-7P
220860-62-8P 220860-63-9P **220860-64-0P**
220860-65-1P **220860-66-2P** **220860-67-3P**
220860-68-4P 220860-69-5P **220860-70-8P** 220860-71-9P
220860-72-0P 220860-73-1P **220860-74-2P**
220860-75-3P 220860-76-4P 220860-77-5P 220860-78-6P
 220860-79-7P 220860-80-0P **220860-81-1P** 220860-82-2P
 220860-83-3P 220860-84-4P 220860-85-5P 220860-86-6P 220860-87-7P
 220860-88-8P 220860-89-9P 220860-91-3P **220860-92-4P**
220860-93-5P 220860-94-6P **220860-95-7P** 220860-98-0P
 220860-99-1P 220861-00-7P 220861-01-8P 220861-02-9P 220861-03-0P
 220861-08-5P 220861-09-6P 220861-10-9P 220861-11-0P 220861-13-2P
 220861-14-3P 220861-15-4P 220861-16-5P 220861-19-8P 220861-21-2P
 220861-22-3P 220861-25-6P 220861-26-7P 304680-78-2P
304680-79-3P 304680-80-6P 304680-81-7P 304680-82-8P
 304680-83-9P 304680-84-0P 304680-85-1P 304680-86-2P 304680-87-3P
 304680-88-4P 304680-89-5P 304680-90-8P 304680-91-9P 304680-92-0P
 304680-93-1P 304680-94-2P 304680-95-3P 304680-96-4P 304680-97-5P
 304680-98-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological
 study); PREP (Preparation)
 (prepn. of substituted 4-oxo-naphthyridine-3-carboxamides as agonists,
 antagonists or inverse agonists for **GABA_A** brain receptors)

IT 64-17-5, Ethanol, reactions 87-13-8, Diethyl ethoxymethylenemalonate
 100-46-9, Benzylamine, reactions 109-73-9, Butylamine, reactions
 4548-45-2, 2-Chloro-5-nitropyridine 17201-43-3, .alpha.-Bromo-p-
 tolunitrile 24424-99-5, Di-tert-butyl dicarbonate 54303-30-9,
 2-(Ethylthio)ethylamine hydrochloride 220861-33-6 220861-34-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant for prepn. of substituted 4-oxo-naphthyridine-3-carboxamides
 as agonists, antagonists or inverse agonists for **GABA_A** brain
 receptors)

IT 2393-23-9P, 4-Methoxybenzylamine 21626-41-5P, 2-Benzylamino-5-
 nitropyridine 21630-48-8P 31594-45-3P, 2-Ethoxy-5-nitropyridine
 34403-48-0P 52025-34-0P, 2-Ethoxy-5-aminopyridine 92808-09-8P
 92808-14-5P 92808-33-8P 220861-28-9P 220861-29-0P 220861-31-4P
 304680-99-7P 304681-00-3P 304681-01-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (reactant for prepn. of substituted 4-oxo-naphthyridine-3-carboxamides
 as agonists, antagonists or inverse agonists for **GABA_A** brain
 receptors)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; DE 2322750 1973 HCAPLUS
- (2) Anon; DE 2407744 1974 HCAPLUS
- (3) Anon; DE 279875 A1 1990
- (4) Anon; DE 279887 A1 1990
- (5) Anon; DE 295360 A5 1991
- (6) Geoffrey, W; Molecular Neuroscience, NeuroReport 1995, V6, P1313
- (7) Haskell; US 4374138 1983 HCAPLUS

- (8) Heindl, J; Eur J Med Chem 1977, V6, P549
 (9) Kondo, K; Patent Abstracts of Japan 1999, V13(260)
 (10) Laruelle; US 4621088 1986 HCAPLUS
 (11) Murakami; US 3953428 1976 HCAPLUS
 (12) Nuebling; US 5378679 1995 HCAPLUS
 (13) White, G; Receptors and Channels 1995, V3, P1 HCAPLUS

L48 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2003 ACS

AN 1999:166616 HCAPLUS

DN 130:196645

TI Preparation of 4-oxonaphthyridine-3-carboxamides as **GABA** brain receptor ligands

IN Albaugh, Pamela; Desimone, Robert W.; Liu, Gang

PA Neurogen Corporation, USA

SO PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D471-04


ICS A61K031-44; C07D471-04; C07D221-00; C07D221-00

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9910347	A1	19990304	WO 1998-US17513	19980824
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2301599	AA	19990304	CA 1998-2301599	19980824
	AU 9891173	A1	19990316	AU 1998-91173	19980824
	AU 753800	B2	20021031		
	EP 1007526	A1	20000614	EP 1998-943352	19980824
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9811362	A	20000822	BR 1998-11362	19980824
	SI 20270	C	20001231	SI 1998-20055	19980824
	JP 2001514181	T2	20010911	JP 2000-507675	19980824
	MX 200001598	A	20001026	MX 2000-1598	20000215
	NO 2000000822	A	20000413	NO 2000-822	20000218
	BG 104192	A	20010531	BG 2000-104192	20000225
	LV 12539	B	20010120	LV 2000-29	20000316
PRAI	US 1997-918180	A	19970825		
	WO 1998-US17513	W	19980824		
OS	MARPAT 130:196645				
GI					



- AB The title compds. I [X is hydrogen, halogen, (un)substituted alkyl, (un)substituted alkoxy or amino; and Y is (un)substituted alkyl, aryl, or heteroaryl] are prepd. I are highly selective agonists, antagonists or inverse agonists for **GABA_A** brain receptors or prodrugs of agonists, antagonists or inverse agonists for **GABA_A** brain receptors. These compds. are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness. In in vitro assays for **GABA_A** receptor activity using rat cortical tissue homogenate and 3H-Flumazenil and diazepam, compds. of this invention showed K_i values of less than 1 μ M.
- ST oxonaphthyridinecarboxamide prepn **GABA** brain receptor ligand; **GABA** brain receptor ligand oxonaphthyridinecarboxamide prepn; anxiolytic oxonaphthyridinecarboxamide prepn; anticonvulsant oxonaphthyridinecarboxamide prepn; benzodiazepine overdose treatment oxonaphthyridinecarboxamide prepn; Down syndrome treatment oxonaphthyridinecarboxamide prepn
- IT **GABA** receptors
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
 (**GABA_A**; prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands)
- IT Mental activity
 (alertness; prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands with effect on alertness)
- IT Mental disorder
 (cognitive; prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands with effect on cognitive disorders)
- IT Cognition
 (disorder; prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands with effect on cognitive disorders)
- IT Anticonvulsants
 Anxiolytics
 (prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands)
- IT **GABA** receptors
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
 (prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands)
- IT Down's syndrome
 (prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands with effect on Down syndrome)
- IT Sleep
 (prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands with effect on sleep)
- IT 220860-38-8P 220860-40-2P 220860-41-3P 220860-42-4P
 220860-43-5P 220860-44-6P 220860-45-7P
 220860-46-8P 220860-47-9P 220860-48-0P 220860-49-1P
 220860-50-4P 220860-51-5P 220860-52-6P 220860-53-7P
 220860-54-8P 220860-55-9P 220860-56-0P 220860-57-1P

220860-58-2P 220860-59-3P 220860-60-6P
220860-61-7P 220860-62-8P 220860-63-9P 220860-64-0P
220860-65-1P 220860-66-2P 220860-67-3P
220860-68-4P 220860-69-5P 220860-70-8P 220860-71-9P
220860-72-0P 220860-73-1P 220860-74-2P
220860-75-3P 220860-76-4P 220860-77-5P 220860-78-6P
220860-79-7P 220860-80-0P 220860-81-1P 220860-82-2P
220860-83-3P 220860-84-4P 220860-85-5P 220860-86-6P 220860-87-7P
220860-88-8P 220860-89-9P 220860-90-2P 220860-91-3P
220860-92-4P 220860-93-5P 220860-94-6P
220860-95-7P 220860-96-8P 220860-97-9P 220860-98-0P
220860-99-1P 220861-00-7P 220861-01-8P 220861-02-9P 220861-03-0P
220861-04-1P 220861-05-2P 220861-06-3P 220861-07-4P 220861-08-5P
220861-09-6P 220861-10-9P 220861-11-0P 220861-12-1P 220861-13-2P
220861-14-3P 220861-15-4P 220861-16-5P 220861-17-6P
220861-18-7P 220861-19-8P 220861-20-1P 220861-21-2P 220861-22-3P
220861-23-4P 220861-25-6P 220861-26-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of oxonaphthyridinecarboxamides as GABA brain receptor ligands)

IT 17658-19-4P

RL: BYP (Byproduct); PREP (Preparation)

(prepn. of oxonaphthyridinecarboxamides as GABA brain receptor ligands)

IT 64-17-5, Ethanol, reactions 74-89-5, Methylamine, reactions 87-13-8, Diethyl ethoxymethylenemalonate 100-46-9, Benzylamine, reactions 108-00-9, N,N-Dimethylethylenediamine 109-73-9, 1-Butanamine, reactions 541-41-3, Ethyl chloroformate 2393-23-9, 4-Methoxybenzylamine 4548-45-2, 2-Chloro-5-nitropyridine 17201-43-3, .alpha.-Bromo-p-tolunitrile 24424-99-5, Di-tert-butyl dicarbonate 54303-30-9 92808-14-5 220861-33-6 220861-34-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of oxonaphthyridinecarboxamides as GABA brain receptor ligands)

IT 21626-41-5P 21630-48-8P 31594-45-3P 34403-48-0P 52025-34-0P
92808-09-8P 92808-33-8P 191871-90-6P 220861-27-8P 220861-28-9P
220861-29-0P 220861-30-3P 220861-31-4P 220861-32-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of oxonaphthyridinecarboxamides as GABA brain receptor ligands)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Allen & Hanburys; DE 2407744 A 1974 HCAPLUS
- (2) Haskell, T; US 4374138 A 1983 HCAPLUS
- (3) Institut Fur Wirkstoffforschung Der Akademie Der Wissenschaften; DD 279875 A 1990 HCAPLUS
- (4) Institut Fur Wirkstoffforschung Der Akademie Der Wissenschaften; DD 279887 A 1990 HCAPLUS
- (5) Institut Fur Wirkstoffforschung Der Akademie Der Wissenschaften; DD 295360 A 1991 HCAPLUS
- (6) Otsuka Pharmaceut Co Ltd; JP 01061461 A 1989 HCAPLUS
- (7) Yamanouchi Pharmaceutical Co Ltd; DE 2322750 A 1973 HCAPLUS

=> fil uspatall

FILE 'USPATFULL' ENTERED AT 16:09:40 ON 29 APR 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:09:40 ON 29 APR 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 141

L49 5 L41

=> d bib abs hitrn tot

L49 ANSWER 1 OF 5 USPATFULL

AN 2002:337995 USPATFULL

TI Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders

IN Villalobos, Anabella, Niantic, CT, UNITED STATES

PI US 2002193360 A1 20021219

AI US 2002-83743 A1 20020226 (10)

PRAI US 2001-272566P 20010301 (60)

DT Utility

FS APPLICATION

LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1737

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a GABA.sub.A inverse agonist or a pharmaceutically acceptable salt thereof; and a nicotine receptor partial agonist, an estrogenic agent, selective estrogen receptor modulator or vitamin E or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The GABA.sub.A inverse agonist, and nicotine receptor partial agonist, estrogen, selective estrogen receptor modulator or vitamin E are present in amounts that render the composition effective enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease, Huntington's disease, memory impairment associated with depression or anxiety, schizophrenia, Down's syndrome, stroke, traumatic brain injury (TBI), AIDS associated dementia and attention deficit disorder. The method of using these compositions is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220860-40-2 220860-45-7 220860-47-9

220860-48-0 220860-50-4 220860-52-6

220860-56-0 220860-58-2 220860-59-3

220860-60-6 220860-62-8 220860-64-0

220860-65-1 220860-66-2 220860-67-3

220860-68-4 220860-70-8 220860-72-0

220860-74-2 220860-75-3 220860-81-1

220860-90-2 220860-92-4 220860-93-5

220860-95-7 220861-17-6 304680-79-3

415678-14-7 415678-15-8

(use of GABAA inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)

L49 ANSWER 2 OF 5 USPATFULL

AN 2002:280830 USPATFULL

TI Substituted 4-oxo-naphthyridine-3-carboxamides: GABA brain receptor ligands

IN Albaugh, Pamela A., Carmel, IN, UNITED STATES

DeSimone, Robert W., Durham, CT, UNITED STATES

Liu, Gang, Oak Park, CA, UNITED STATES

PA Neurogen Corporation, Corporation of the State of Delaware, Branford, CT
(U.S. corporation)
PI US 2002156280 A1 20021024
AI US 2002-114743 A1 20020402 (10)
RLI Continuation of Ser. No. US 2000-634093, filed on 8 Aug 2000, GRANTED,
Pat. No. US 6399604 Continuation of Ser. No. US 1998-139456, filed on 25
Aug 1998, GRANTED, Pat. No. US 6143760
PRAI US 1997-56799P 19970825 (60)
DT Utility
FS APPLICATION
LREP Steven J. Sarussi, McDonnell Boehnen Hulbert & Berghoff, 32nd Floor, 300
S. Wacker Drive, Chicago, IL, 60606
CLMN Number of Claims: 106
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1878
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses structures of the Formula ##STR1##

or the pharmaceutically acceptable non-toxic salts thereof wherein:

X is hydrogen, halogen, (un)substituted alkyl, (un)substituted alkoxy or
amino; and

Y is (un)substituted alkyl, aryl, or heteroaryl,

which compounds are highly selective agonists, antagonists or inverse
agonists for GABAA brain receptors or prodrugs of agonists, antagonists
or inverse agonists for GABAA brain receptors. These compounds are
useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep,
cognitive and seizure disorders, and overdose with benzodiazepine drugs
and for enhancement of alertness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220860-43-5P 220860-44-6P 220860-45-7P
220860-47-9P 220860-48-0P 220860-50-4P
220860-56-0P 220860-58-2P 220860-59-3P
220860-60-6P 220860-62-8P 220860-64-0P
220860-65-1P 220860-66-2P 220860-67-3P
220860-68-4P 220860-70-8P 220860-72-0P
220860-74-2P 220860-75-3P 220860-81-1P
220860-92-4P 220860-93-5P 220860-95-7P
304680-79-3P

(prepn. of substituted 4-oxo-naphthyridine-3-carboxamides as agonists,
antagonists or inverse agonists for GABAA brain receptors)

L49 ANSWER 3 OF 5 USPATFULL

AN 2002:273463 USPATFULL

TI Combination use of acetylcholinesterase inhibitors and GABAA inverse
agonists for the treatment of cognitive disorders

IN Villalobos, Anabella, Niantic, CT, UNITED STATES

Cassella, James V., Guilford, CT, UNITED STATES

Rajachandran, Lavanya, Wallingford, CT, UNITED STATES

PI US 2002151591 A1 20021017

AI US 2001-976347 A1 20011012 (9)

PRAI US 2000-241145P 20001017 (60)

DT Utility

FS APPLICATION

LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY,
10017-5612

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 1102

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a composition for treating a cognitive disorder, which comprises an acetylcholinesterase inhibitor, and a GABA.sub.A inverse agonist selected from a compound of the formula. ##STR1##

where X and Y are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220860-40-2 220860-45-7 220860-47-9

220860-48-0 220860-50-4 220860-52-6

220860-56-0 220860-58-2 220860-59-3

220860-60-6 220860-62-8 220860-64-0

220860-65-1 220860-66-2 220860-67-3

220860-68-4 220860-70-8 220860-72-0

220860-74-2 220860-75-3 220860-81-1

220860-90-2 220860-92-4 220860-93-5

220860-95-7 220861-17-6 304680-79-3

415678-14-7 415678-15-8

(combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of cognitive disorders)

L49 ANSWER 4 OF 5 USPATFULL

AN 2002:129963 USPATFULL

TI Substituted 4-OXO-napthyridine-3-carboxamides; GABA brain receptor ligands

IN Albaugh, Pamela A., Clinton, CT, United States

DeSimone, Robert W., Durham, CT, United States

Liu, Gang, Agoura, CA, United States

PA Neurogen Corporation, Branford, CT, United States (U.S. corporation)

PI US 6399604 B1 20020604

AI US 2000-634093 20000808 (9)

RLI Continuation of Ser. No. US 1998-139456, filed on 25 Aug 1998, now patented, Pat. No. US 6143760

PRAI US 1997-56799P 19970825 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Seaman, D. Margaret

LREP McDonnell Boehnen Hulbert & Berghoff

CLMN Number of Claims: 107

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 2018

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses structures of the Formula ##STR1##

or the pharmaceutically acceptable non-toxic salts thereof wherein:

X is hydrogen, halogen; (un)substituted alkyl, (un)substituted alkoxy or amino; and

Y is (un)substituted alkyl, aryl, or heteroaryl, which compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220860-43-5P 220860-44-6P 220860-45-7P

220860-47-9P 220860-48-0P 220860-50-4P

220860-56-0P 220860-58-2P 220860-59-3P

220860-60-6P 220860-62-8P 220860-64-0P
220860-65-1P 220860-66-2P 220860-67-3P
220860-68-4P 220860-70-8P 220860-72-0P
220860-74-2P 220860-75-3P 220860-81-1P
220860-92-4P 220860-93-5P 220860-95-7P
304680-79-3P

(prepn. of substituted 4-oxo-naphthyridine-3-carboxamides as agonists, antagonists or inverse agonists for GABA_A brain receptors)

L49 ANSWER 5 OF 5 USPTFLL
AN 2000:150180 USPTFLL
TI Substituted 4-oxo-naphthyridine-3-carboxamides: GABA brain receptor ligands
IN Albaugh, Pamela A., Clinton, CT, United States
DeSimone, Robert W., Durham, CT, United States
Liu, Gang, Agoura, CA, United States
PA Neurogen Corporation, Branford, CT, United States (U.S. corporation)
PI US 6143760 20001107
AI US 1998-139456 19980825 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Seaman, D. Margaret
LREP McDonnell Boenn Hulbert & Berghoff, Sarussi, Steven J.
CLMN Number of Claims: 110
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1791

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses structures of the Formula ##STR1## or the pharmaceutically acceptable non-toxic salts thereof wherein: x is hydrogen, halogen, (un)substituted alkyl, (un)substituted alkoxy or amino; and

Y is (un)substituted alkyl, aryl, or heteroaryl,

which compounds are highly selective agonists, antagonists or inverse agonists for GABA_A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA_A brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220860-43-5P 220860-44-6P 220860-45-7P
220860-47-9P 220860-48-0P 220860-50-4P
220860-56-0P 220860-58-2P 220860-59-3P
220860-60-6P 220860-62-8P 220860-64-0P
220860-65-1P 220860-66-2P 220860-67-3P
220860-68-4P 220860-70-8P 220860-72-0P
220860-74-2P 220860-75-3P 220860-81-1P
220860-92-4P 220860-93-5P 220860-95-7P
304680-79-3P

(prepn. of substituted 4-oxo-naphthyridine-3-carboxamides as agonists, antagonists or inverse agonists for GABA_A brain receptors)

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 120014-06-4 REGISTRY

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (.+-.)-E 2020

CN **Donepezil**

FS 3D CONCORD

DR 142057-79-2

MF C24 H29 N O3


CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MRCK*, MSDS-OHS, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

225 REFERENCES IN FILE CA (1957 TO DATE)

8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

226 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=>